David Young

David Young was the founder of GloboMax LLC, founded in 2003, where the title held was Chief Executive Officer.
Dr. Young is the founder of Processa Pharmaceuticals, Inc., founded in 2011, holding the titles of Director and President-Research & Development.
Dr. Young was the founder of Promet Therapeutics LLC, founded in 2015, where the titles held were Chief Executive & Financial Officer.
Former jobs include Director, Chief Executive & Financial Officer at Heatwurx, Inc.; Managing Director-Clinical Research Unit at the University of Maryland; President & Executive Director at AGI Therapeutics, Inc. from 2006 to 2009; President & Executive Director at AGI Therapeutics Plc from 2006 to 2009; Chief Scientific Officer at Questcor Pharmaceuticals, Inc. from 2009 to 2014; EVP-Strategic Drug Development Division at ICON plc from 2003 to 2006; and Associate Professor at the University of Maryland School of Pharmacy from 1986 to 1997.
Education includes a doctorate from the University of Southern California, graduate studies at the University of Wisconsin, and undergraduate studies at the University of California, Berkeley.